{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:49Z","timestamp":1791474709146,"version":"4.3.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Follicular Lymphoma (FL) has a 10-year mortality rate of 20%, and this is mostly related to lymphoma progression and transformation to higher grades. In the era of personalized medicine it has become increasingly important to provide patients with an optimal prediction about their expected outcomes. The objective of this work was to apply machine learning (ML) tools on gene expression data in order to create individualized predictions about survival in patients with FL. Using data from two different studies, we were able to create a model which achieved good prediction accuracies in both cohorts (c-indexes of 0.793 and 0.662 in the training and test sets). Integration of this model with m7-FLIPI and age rendered high prediction accuracies in the test set (cox c-index 0.79), and a simplified approach identified 4 groups with remarkably different outcomes in terms of survival. Importantly, one of the groups comprised 27.35% of patients and had a median survival of 4.64 years. In summary, we have created a gene expression-based individualized predictor of overall survival in FL that can improve the predictions of the m7-FLIPI score.<\/jats:p>","DOI":"10.3389\/fonc.2021.705010","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T04:37:18Z","timestamp":1641789438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models"],"prefix":"10.3389","volume":"11","author":[{"given":"Adri\u00e1n","family":"Mosquera Orgueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cid L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Peleteiro Ra\u00edndo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Abu\u00edn Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose \u00c1ngel","family":"D\u00edaz Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Sonia","family":"Gonz\u00e1lez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Antelo Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bao P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roi","family":"Ferreiro Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aliste Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Mateo","family":"P\u00e9rez Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ximo Francisco","family":"Fraga Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mozas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Bello L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular Lymphoma in the Modern Era: Survival, Treatment Outcomes, and Identification of High-Risk Subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) Score in an Independent Series of Follicular Lymphoma Patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A Simplified Scoring System in De Novo Follicular Lymphoma Treated Initially With Immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-019-0269-6","article-title":"Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) With Lymphopenia (FLIPI-L): A Predictor for Overall Survival and Histologic Transformation","volume":"9","author":"Yang","year":"2020","journal-title":"Blood Cancer J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of Gene Mutations in Risk Prognostication for Patients Receiving First-Line Immunochemotherapy for Follicular Lymphoma: A Retrospective Analysis of a Prospective Clinical Trial and Validation in a Population-Based Registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A Gene-Expression Profiling Score for Prediction of Outcome in Patients With Follicular Lymphoma: A Retrospective Training and Validation Analysis in Three International Cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1186\/s12885-020-07492-y","article-title":"Improved Personalized Survival Prediction of Patients With Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling","volume":"20","author":"Mosquera Orgueira","year":"2020","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198580","article-title":"Follicular Lymphomas With and Without Translocation T(14;18) Differ in Gene Expression Profiles and Genetic Alterations","volume":"114","author":"Leich","year":"2009","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156594","article-title":"Removing Batch Effects From Longitudinal Gene Expression - Quantile Normalization Plus ComBat as Best Approach for Microarray Transcriptome Data","volume":"11","author":"M\u00fcller","year":"2016","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1214\/08-AOAS169","article-title":"Random Survival Forests","volume":"2","author":"Ishwaran","year":"2008","journal-title":"Ann Appl Statist"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic Risk Models Predict Early Progression of Follicular Lymphoma After First-Line Immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous Stem Cell Transplantation for Patients With Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials From the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab Combined With Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma (GALEN): A Multicentre, Single-Arm, Phase 2 Study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0757-z","article-title":"TMEM30A Loss-of-Function Mutations Drive Lymphomagenesis and Confer Therapeutically Exploitable Vulnerability in B-Cell Lymphoma","volume":"26","author":"Ennishi","year":"2020","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13578-016-0121-7","article-title":"MAP4K4: An Emerging Therapeutic Target in Cancer","volume":"6","author":"Gao","year":"2016","journal-title":"Cell Biosci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16117","article-title":"The Landscape of Genetic Mutations in Patients With Chronic Lymphocytic Leukaemia and Complex Karyotype","volume":"187","author":"Strati","year":"2019","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1051\/medsci\/20173305004","article-title":"Du Neuf Dans L\u2019oncogen\u00e8se Mol\u00e9culaire Des Lymphomes: R\u00f4le Du G\u00e8ne SETD2 Dans Les Lymphomes T De L\u2019intestin [Molecular Oncogenesis of Lymphomas: Role of the SETD2 Gene in Intestinal T-Cell Lymphomas]","volume":"33","author":"Vallois","year":"2017","journal-title":"Med Sci (Paris)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2137","article-title":"Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function: Potential Impact on Survival and Risk of Transformation","volume":"31","author":"Kiaii","year":"2013","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001185","article-title":"A 4-Gene Leukemic Stem Cell Score can Independently Predict the Prognosis of Myelodysplastic Syndrome Patients","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short Regimen of Rituximab Plus Lenalidomide in Follicular Lymphoma Patients in Need of First-Line Therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.705010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T16:38:44Z","timestamp":1641832724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.705010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":26,"alternative-id":["10.3389\/fonc.2021.705010"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.705010","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"article-number":"705010"}}